Europe Contraceptives Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Europe Contraceptives Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The European contraceptives market is expected to witness a CAGR of 7.15% during the forecast period (2022-2027).

COVID-19 has significantly impacted the European contraceptive market due to the barriers to access to contraceptives due to travel restrictions. According to the European Parliamentary Forum (EPF) report published in September 2021, some of the sexual and reproductive health services that were most severely impacted by restrictions were counseling services for contraception. According to the survey, there are considerable obstacles to obtaining the prescriptions needed to purchase contraceptive methods from pharmacies, which has caused some women to discontinue using the pill. For instance, According to the report published in September 2021 by the European Parliamentary Forum for Sexual and Reproductive Rights, 12.5% of Spanish women who quit using the hormonal contraceptive pill discontinued using the pill because getting a prescription was difficult. This has impacted the market growth due to the decline in sales of contraceptives in Europe.

Certain factors that are driving the market growth include the increasing prevalence of sexually transmitted diseases (STDs), the growing rate of unintended pregnancies, the increasing demand for modern contraceptive methods, and rising government initiatives.

Rising initiatives from the European countries on contraception for their residents is expected to drive the growth of this market in Europe. For instance, in December 2021, in order to prevent young women from stopping their use of contraception because they cannot afford it, France will begin offering free birth control to all women under 25. The programme, which potentially help three million women, includes coverage for the pill, intra uterine devices (IUDs), contraceptive patches, and other steroid hormone-based techniques. Such initiatives from the government will lead to increased production of contraceptives, driving the market growth.

Furthermore, rising approvals from the European Union on oral contraceptives will also drive the market growth over the forecast period. For instance, in May 2021, European Commission has accepted the registration application for the novel combined oral contraceptive Estelle. that is developed by Mithra, a company dedicated to Women’s Health. Such approvals will lead to increased adoption of oral contraceptives in Europe due to rise in availability of contraceptives in the market.

Contribution toward the growth of the contraceptives market is a necessity in order to avoid unwanted pregnancies and their complications. A high percentage of women who are sexually active do not want to become pregnant. It is also observed that more than half of the women identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain, and acne, as reasons for use. These are some of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market are the increasing incidence of STDs and the rapid increase in population. Government initiatives promoting the use of contraceptives to avoid unnecessary births and the health benefits from using the contraceptives have also been important players in the growth of the market.

However, factors, such as side effects using contraception and socio-cultural issues associated with contraception are expected to hinder the market growth.

Key Market TrendsCondoms are Expected to hold its Highest Market Share in the Devices Type

Condom use has significantly increased in adolescents due to easy availability and convenience. Furthermore, effective protection from sexually transmitted infections and demand from the young population to enhance their sexual experience is expected to aid the product demand.

Rising initiatives from European governments for safe sex in their countries especially among teenagers are expected to drive the growth of this segment in Europe. For instance, according to the news in March 2021, 96% of France's schools have condom vending machines to encourage healthy sex and lower the chance of teen pregnancy. Such initiatives in developed European countries will lead to increased adoption of condoms, driving the segment growth.

Furthermore, according to the study titled 'Principles of condom provision programs in prisons from the standpoint of European prison health experts: a qualitative study' in January 2021, the findings of this study can aid in the design and implementation of condom distribution programs that are acceptable, accessible, and of high quality within prisons, hence reducing the incidence of sexually transmitted diseases in prisons. Such initiatives and launch of condon provision programs will also lead to rise in adoption of condoms in prisons, driving this segment growth.

Moreover, according to the study titled 'Effects of a Novel Erectogenic Condom on Men and Women’s Sexual Pleasure: Randomized Controlled Trial' in published in January 2022 in United Kingdom, CSD500, a novel condom appears to hold significant potential for its role as a condom that could improve men and women’s sexual pleasure. Such studies is expected to further drive this segment growth.

In addition, the availability of different variants under the brands with high-quality standards, cost-effectiveness, and easy access from supermarkets, drug stores, and e-commerce platforms paved the way for this verticle.

United Kingdom Holds a Significant Share in the Europe Contraceptives Market over the Forecast Period.

The United Kindom is expected to hold a significant share due to the rise in sexually transmitted diseases, and initiatives taken by the key market players for the launch of new products, among others.

According to the Government of United Kingdom data published in September 2021, the number of new cases of sexually transmitted infections in 2020 includes Chlamydia 161,672, Gonorrhoea 57,084, Herpes 20,530, Syphilis 6,926, Warts-27,473, Non-specific genital infection (NSGI) 15,705, Pelvic inflammatory disease (PID) and epididymitis 10,572. Such a high incidence of sexually transmitted infections in the United Kingdom is expected to drive market growth in this region due to the rise in the adoption of contraceptives in the United Kingdom.

Furthermore, in July 2021, HRA Pharma Consumer Healthcare company received authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) for the launch of the first type of contraceptive pill that will be available to buy in the United Kingdom without a prescription following a pharmacist consultation, that make it easier for some women to access and therefore use. In addition, in July 2021, United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has also granted Maxwellia’s Lovima, a contraceptive pill that can be sold over the counter without a prescription. These authorizations in the United Kindgom is anticipated to drive the market growth in this region, due to rise in adoption of contraceptives.

Moreover, according to the news published in February 2022, condoms sales have shot up since lockdown restrictions eased in the United Kingdom. The rise in sales of condoms in the United Kingdom will further drive the market growth in this region.

Therefore, owing to the above mentioned factors, the market studied is expected to drive in the United Kingdom.

Competitive Landscape

The European contraceptive market is highly competitive and consists of a number of major players. The factors impacting the market growth include a rise in sexually transmitted diseases, key initiatives adopted by the market players, rise in initiatives from the government, among others. Some of the key market players in the European contraceptives market include Actavis PLC, Agile Therapeutics, ANI Pharmaceuticals Inc., Bayer Healthcare, Fuji Latex Co., Ltd, Johnson & Johnson Ltd, HRA Pharma, Pfizer, Teva Pharmaceuticals Ltd, the Female Health Company, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.